Status:
COMPLETED
Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women
Lead Sponsor:
CHU de Quebec-Universite Laval
Conditions:
Hot Flashes
Eligibility:
FEMALE
40-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal wom...
Detailed Description
Humans, along with the other primates, are unique among animal species in having adrenals that secrete large amounts of the inactive precursor steroids dehydroepiandrosterone (DHEA) and especially its...
Eligibility Criteria
Inclusion
- Healthy postmenopausal women with 50 or more moderate to severe hot flushes.
- Women between 40 to 70 years of age.
Exclusion
- Body mass index (BMI) of 35 kg/m2 or more.
- Significant metabolic and endocrine diseases.
- Diagnosis of cancer.
- Use of steroids or drugs that interfere with the metabolism of estrogen.
- Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization.
- Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization.
- Palpable fibroids or uterine prolapse: Grade 2 or 3.
- Cigarette smoking
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00317148
Start Date
August 1 2005
End Date
December 1 2007
Last Update
April 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique des Traitements Hormonaux
Sainte-Foy, Quebec, Canada, G1V 4G2